You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Data Analytics and Machine Learning Toolkit to Accelerate Materials Design and Processing DevelopmentSBC: CFD RESEARCH CORPORATION Topic: N19AT020
The US Navy has identified refractory high entropy alloys (RHEAs) and metal additive manufacturing (AM) as enabling technologies to meet performance and sustainability targets for shipboard and aircraft systems. Key challenges include designing RHEAs and optimizing metal AM to achieve desired material properties for Navy propulsion applications. Developing materials and processes via traditional e ...STTR Phase II 2020 Department of DefenseNavy
SBC: EXCITING TECHNOLOGY LLC Topic: AF19AT006
Exciting Technology, LLC (ET) and University of Dayton Research Institute (UDRI) along with their Transition partner Lockheed Martin Coherent Technologies (LMCT) plan to extend the Phase I phenomenology and wave optics simulations, and build a vibration imaging LiDAR for target phenomenology characterizations in controlled environments. In addition, the team provides an optional path to accelera ...STTR Phase II 2020 Department of DefenseAir Force
SBC: ATA ENGINEERING, INC. Topic: MDA18T002
Recent advances in the hypersonic system capabilities of adversary nations threaten the battlespace supremacy of US forces. Missile defense systems capable of extended high-g maneuvering at stratospheric altitudes and hypersonic Mach numbers will provide the MDA with additional flexibility in defending the US against emerging hypersonic threats. A key enabling technology for the deployment of such ...STTR Phase II 2020 Department of DefenseMissile Defense Agency
SBC: Traclabs Inc. Topic: AF19AT004
This is an augmentation of a robotic installation Robin AFB GXMG has been using for over a decade. Each C-130 prop that needs grinding for remanufacture will no longer be treated exactly the same (since they are not). 3D sensing will adapt a grinding process to the exact blade geometry. Furthermore, if a prop need to be processed further (to remove pitting or scratches), the system will target onl ...STTR Phase II 2020 Department of DefenseAir Force
Toolset For Prediction of Carbon-Carbon Aeroshell Properties Based On Constituent Materials And Manufacturing Process ParametersSBC: ATA ENGINEERING, INC. Topic: AF19AT021
Carbon-carbon (C-C) composites are used in the fabrication of aeroshells and thermal protection systems (TPS) in hypersonic and atmospheric reentry applications because they maintain their strength at elevated temperatures and have desirable thermal conductivity properties. Although these materials have been used in mission-critical components for decades, the effects of variations in processing m ...STTR Phase II 2020 Department of DefenseAir Force
SBC: Flow Pharma, Inc. Topic: CBD18A002
Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
SBC: Sano Chemicals, Inc. Topic: NIAID
Project Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Compatibility between Brain-Computer Interface and High-Efficiency Augmentative and Alternative Communication SystemsSBC: Prentke Romich Company Topic: NIDCD
Compatibility between Brain-Computer Interface and High Efficiency Augmentative and AlternativeCommunication Systems: Phase II ABSTRACT Brain-computer interfaces (BCI) enable text production for people who cannot move, but have only simple communication interfaces and are not widely used. Augmentative and alternative communication (AAC) systems are widely used and give efficient and precise commun ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related DementiasSBC: Whiplash Technology, Inc. Topic: NIA
PROJECT ABSTRACT Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an innovative web/mobile application for family ca ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.SBC: ARCHER PHARMACEUTICALS, INC. Topic: NIA
Pathological hallmarks of Alzheimerandapos;s disease (AD) include extracellular deposits of Aβ peptides, intraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammation. Most proposed AD disease modifying therapies have focused on strategies that reduce brain Aβ/amyloid or tau pathological accumulation. However, such approaches have been unsuccessful in late stage AD clin ...STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health